A Phase II Clinical Study of BBI503 in Asymptomatic Recurrent Ovarian Cancer Patients With CA-125 Elevation
Phase of Trial: Phase II
Latest Information Update: 09 Apr 2018
At a glance
- Drugs Amcasertib (Primary)
- Indications Fallopian tube cancer; Glandular and epithelial neoplasms; Ovarian cancer; Peritoneal cancer
- Focus Biomarker; Therapeutic Use
- Sponsors Boston Biomedical
- 03 Apr 2018 Status changed from active, no longer recruiting to completed.
- 10 Jun 2017 Biomarkers information updated
- 09 Mar 2017 Status changed from recruiting to active, no longer recruiting.